anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Gustilo type III open fractures involve extensive soft tissue damage and wound contamination that pose significant infection risks. The historical standard for antibiotic prophylaxis has been cefazolin and gentamicin. We conducted a retrospective cohort study of lower extremity type III open fractures treated with ceftriaxone alone for prophylaxis. Eighty-six patients were identified. Nearly all (98%) were managed with appropriate antibiotics, but only 55 (64%) received prophylaxis within 1 hour. Overall, there were 12 infections. This infection rate was not statistically different than the reported literature (14% vs 19%, P = .20). The infection rate between those who received antibiotics within 1 hour was not statistically different from those who got it beyond 1 hour (15% vs 13%, P = .98). In conclusion, the use of ceftriaxone as monotherapy for antibiotic prophylaxis in lower extremity type III open fractures is not statistically different than the use of historic prophylactic regimens.
BACKGROUND: Cancer cachexia is associated with impaired functional and nutritional status and worse clinical outcomes. Global Leadership Initiative in Malnutrition (GLIM) consensus recommended the application of GLIM criteria to diagnose malnutrition in patients with cachexia. However, few previous study has applied the GLIM criteria in patients with cancer cachexia.
METHODS: From July 2014 to May 2019, patients who were diagnosed with cancer cachexia and underwent radical gastrectomy for gastric cancer were included in this study. Malnutrition was diagnosed using the GLIM criteria. Skeletal muscle index was measured using abdominal computed tomography (CT) images at the third lumbar vertebra (L3) level. Hand-grip strength and 6-meters gait speed were measured before surgery.
RESULTS: A total of 356 patients with cancer cachexia were included in the present study, in which 269 (75.56%) were identified as having malnutrition based on the GLIM criteria. GLIM-defined malnutrition alone did not show significant association with short-term postoperative outcomes, including complications, costs or length of postoperative hospital stays. The combination of low hand-grip strength or low gait speed with GLIM-defined malnutrition led to a significant predictive value for these outcomes. Moreover, low hand-grip strength plus GLIM-defined malnutrition was independently associated with postoperative complications (OR 1.912, 95% CI 1.151-3.178, P = 0.012). GLIM-defined malnutrition was an independent predictive factor for worse OS (HR 2.310, 95% CI 1.421-3.754, P = 0.001) and DFS (HR 1.815, 95% CI 1.186-2.779, P = 0.006) after surgery. The addition of low hand-grip strength or low gait speed to GLIM-defined malnutrition did not increase its predictive value for survival.
CONCLUSION: GLIM-defined malnutrition predicted worse long-term survival in gastric cancer patients with cachexia. Gait speed and hand-grip strength added prognostic value to GLIM-defined malnutrition for the prediction of short-term postoperative outcomes, which could be incorporated into preoperative assessment protocols in patients with cancer cachexia.
PURPOSE: To provide title compsn. which is useful for co-catalyst for oxidation and artificial blood material which can be preserved for a prolonged period of time and which makes it possible in the form of an aq. soln. to carry out reversibly the adsorption and the desorption of oxygen, by a method wherein a specified covalent bond type polymer-metal complex is blended with an N-alkylimidazole.  
     CONSTITUTION: There are provided covalent bond type polymer-metal complexs for the adsorption and the desorption of oxygen which are in the form of aq. soln., obtd. by blending (A) a covalent bond type polymer metal complex of formula I [wherein m+n≥10; 1/2(m+n)≥n≥1; l is 0, 1; K≥10(m+n); P is a complex gp. of formula II; R 1  is gp. of formula III; R 2  is gp. of formula IV or V; M is Fe (II)] with (B) an N-alkylimidazole in an amount of 2W5mol of (B) per mole of complex moiety unit of (A). When the compsn. are used in the form of aq. soln., the adsorption and the desorption of oxygen can be carried out. Solids obtd. by the drying such as freeze drying of the compsn. are inert to oxygen and can be preserved in air for a prolonged period of time. When water is added to the solids, the adsorption-desorption capability can be recovered. 
     COPYRIGHT: (C)1980,JPO&Japio
Participants will be randomized into one of three groups. In this arm, participants will perform bladder instillations using a 50ml solution of gentamicin mixed with saline, 2 times per day. A formulation derived from 480 mg gentamicin sulfate diluted in 1 L normal saline will be used for instillation. Participants will be blinded during the study and will not know if they are receiving gentamicin or placebo (saline alone).
PURPOSE: A bio-imaging nanoparticle is provided to ensure excellent water solubility, target selectivity, and bio affinity and to early diagnose diseases. CONSTITUTION: A bio-imaging nanoparticle contains: a core nanoparticle; a binding layer which contains organic ligand(20), surfactant(14) and a polyoxyalkylene derivative(16) of fatty acid ester and covers the core nanoparticle; and a functional molecule(18). The organic ligand is conjugated on the surface of the core nanoparticle. The surfactant is conjugated on a part of the surface, in which organic ligand is not conjugated. The core nanoparticle contains a core(10) and a shell(12). The functional molecule is a bio affinity molecule, target-oriented molecule, or a conjugate or mixture thereof.
Most preterm babies have the umbilical cord clamped within 10 seconds of birth. Placental transfusion is a simple way of giving the baby extra blood at birth by delaying the clamping of the umbilical cord by 60 seconds or more. There is promising evidence from randomised trials that placental transfusion in babies less than 37 weeks of pregnancy may improve their blood pressure, reduce the number of blood transfusions needed and decrease bleeding into the brain, bowel disease and infection. However, we not know if babies born before 30 weeks of pregnancy benefit or if placental transfusion increases or decreases death or childhood disability. Despite this uncertainty more doctors are recommending that all very preterm babies are given a placental transfusion at birth. It is important to find out if placental transfusion does more good than harm, before it becomes even more widely used.

The Australian Placental Transfusion Study will enrol at least 1600 women who will give birth to babies born less than 30 weeks of gestation. These participants will be randomly assigned to either standard treatment where the umbilical cord is clamped within 10 seconds of birth or a second method where the umbilical cord will be clamped after waiting for 60 seconds or more at birth while the baby is being held below the level of the placenta. The main research question is whether placental transfusion reduces death and disability when the baby is discharged from hospital and into childhood.
The invention relates to methods for the application of a protective film to all types of powders in order to make them more inert to chemical and physical attack. This film is obtained with polymers containing various percentages of Si and with procedures conducted with and without electrical fields in which the operations of granulation and covering the powders and granules are conducted simultaneously. The product is obtained by atomisation of a suspension of the powder in a suitable organic solvent, in which the polymer can be dissolved, obtained with a rotating disk of a suitable material with good electrical conductivity. The resulting product has a different density and greater fluidity and, above all, greater stability than the starting material. Film-forming technologies also permit the design of simpler forms of delayed-dissolution pharmaceuticals and/or masking of the taste. The processes described are suitable for use on production lines of particularly labile products thus reducing to a minimum the difficulties involved in treating them.
NEW MATERIAL: Recombinant plasmid pTPGIF2 having a size of 4,660 base pairs and a structure obtained by inserting a DNA having a size of 52 base pairs and containing a sequence coding somatostatin into a BamHI incision site of a plasmid vector pTP70-1 capable or fusing a heteropeptide to a carboxy-terminal of a dihydrofolic acid reductase gene of  E. coli . USE: Producton of fused protein containing somatostatin. 
     PREPARATION: A somatostatin gene is integrated into a plasmid vector pTP70-1. pTPGIF2 is kept in stable state when introduced into  E. coli . C600 strain. The  E. coli . C600 train containing pTPGIF2 is deposited in Fermentation Research institute as FERM BP-1577.
An oil-in-water composition comprises a dispersed oil phase, a continuous aqueous phase and a water phase thickener. The oil phase has a viscosity of 400-15000 mPa·s at 25°C. An absolute difference in refractive index between the oil phase and the aqueous phase is 0.05 or above. The oil phase is suspended in the aqueous phase. The water phase thickener contains no hydrophobic group. The oil phase of the oil-in-water composition is stably suspended in the aqueous phase in the form of externally visible droplets, and can prevent problems, such as rupture of the oil phase or separation of the oil phase and the aqueous phase, caused by jolts during the transportation and storage processes.
In this study, patients will be observed who receive an E-vita OPEN NEO implant for the treatment of thoracic aneurysm or acute or chronic thoracic dissection. E-vita OPEN NEO will be implanted according to the instructions for use and at the discretion of the treating physician. Participating physicians will provide their observations collected during routine care for patients treated with E-vita OPEN NEO. Written informed consent, specifically allowing the use of clinical records for this observational study, will be obtained from every patient prior to data collection. The period of data collection will be approximately 24 months from the date of intervention for each patient. Source data verification will be performed on 100% of the patients; data from all the visits that was provided in the database will be reviewed and verified against existing source documents. Complete DICOM image files of the CT scans will be sent to the CoreLab for independent evaluation.
The invention provides an automatic injection device for providing a subcutaneous injection of a substance into a user. The automatic injection device comprises a housing, a syringe movably disposed in the housing, and a syringe actuation component. The syringe includes a plunger for first moving the syringe such that the needle projects from a first end of the housing, and subsequently applying pressure to the bung. The plunger includes a rod having a compressible central portion and a flange between a second end of the rod and the compressible central portion. The device further comprises a biasing mechanism for biasing the plunger, the biasing mechanism is disposed about the second end of the rod between the flange and the second end of the housing. The automatic injection device offers safety advantages, is less painful and includes a hidden needle.
The present invention relates to the technical field of a medical detecting reagent. A CT liver specificity contrast medium is characterized in that the contrast medium is specifically collected on the liver by the phagocytosis of kupffer cells of the liver reticuloendothelial system for enhancing the sensitivity and the specificity of CT diagnosis. The present research on a macromolecular CT liver specificity contrast medium or a granular CT liver specificity contrast medium focuses on using a liposome as a carrier for enwrapping a CT conventional contrast medium; the defects of low enwrapping rate, low medicine carrying quantity, unstable preparation, etc. universally exist. The present invention provides a liver specificity CT contrast medium and a preparation method thereof. Ethyl cellulose is adopted as a carrier for enwrapping a triiodo isophthalic acid derivate for obtaining an iodic ethyl cellulose microsphere.
BACKGROUND: As the population ages, musculoskeletal disorders are a prominent contributory factor to loss of mobility and autonomy. Pain is a predictor of disability and worsening frailty and the role of the chronic pain specialist in the management of this cohort cannot be overstated. With growing requirements for pain specialists, we sought to identify barriers to recruitment within this specialty.
AIMS: Establish baseline attitudes and perceived barriers towards a career in pain medicine among Irish anaesthesiology trainees. Suggest a framework to improve recruitment to the specialty.
METHODS: Ethical approval was obtained. A web-based questionnaire was sent to all anaesthesiologists in training in the Republic of Ireland. Data was analyzed using SPSS.
RESULTS: Two hundred forty-eight trainees received the questionnaire, 59 responded. 54.2% male, 45.8% female. 79.7% had previous clinical exposure to pain medicine, most of whom had spent over one month with a service. Only 10.2% of respondents were considering a career in pain medicine. Factors that attracted trainees to the subspeciality included: interventional practice (81%), variation in clinical practice (66.7%), autonomy of practice (61.9%) and perceived good work-life balance (42.9%). Deterrents from the subspecialty included a psychologically challenging patient cohort (69.5%), frequency of clinics (50.8%), and additional exams (32.2%). When asked how to improve engagement with the speciality, 62% suggested earlier exposure to the speciality and 32.2% suggested increased frequency of formal teaching and workshops.
CONCLUSIONS: Increased exposure of trainees to the specialty during early stages of training may improve future recruitment to the subspecialty in Ireland.
Zinc metabolism at the cellular level is critical for many biological processes in the body. A key observation is the disruption of cellular homeostasis, often coinciding with disease progression. As an essential factor in maintaining cellular equilibrium, cellular zinc has been increasingly spotlighted in the context of disease development. Extensive research suggests zinc's involvement in promoting malignancy and invasion in cancer cells, despite its low tissue concentration. This has led to a growing body of literature investigating zinc's cellular metabolism, particularly the functions of zinc transporters and storage mechanisms during cancer progression. Zinc transportation is under the control of two major transporter families: SLC30 (ZnT) for the excretion of zinc and SLC39 (ZIP) for the zinc intake. Additionally, the storage of this essential element is predominantly mediated by metallothioneins (MTs). This review consolidates knowledge on the critical functions of cellular zinc signaling and underscores potential molecular pathways linking zinc metabolism to disease progression, with a special focus on cancer. We also compile a summary of clinical trials involving zinc ions. Given the main localization of zinc transporters at the cell membrane, the potential for targeted therapies, including small molecules and monoclonal antibodies, offers promising avenues for future exploration.
Safety and early efficacy of CEND-1 in combination with nab-paclitaxel (125mg/m\^2) and gemcitabine (1000mg/m\^2) will be evaluated (dosing on Days 1, 8, 15 of the 28-day treatment cycle). Treatment cycles will be repeated every 4 weeks based on toxicity and response. Treatment may continue as long as there is perceived benefit or until disease progression.
The present invention relates to novel immune/hematopoietic-related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "immune/hematopoietic antigens", and the use of such immune/hematopoietic antigens for detecting immune/hematopoietic-related diseases and/or disorders, particularly the presence of cancer and cancer metastases of cells of hematopoietic origin. More specifically, isolated immune/hematopoietic associated nucleic acid molecules are provided encoding novel immune/hematopoietic associated polypeptides. Novel immune/hematopoietic polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human immune/hematopoietic associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the immune system or cells and tissues associated with hematopoiesis, including cancers of cells of hematopoietic origin, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.
A dental impression material comprises a water soluble (e.g sodium, potassium or ammonium) alginate, a gelling agent therefor (e.g. calcium or lead sulphate) and 2-25% by weight of a water soluble film forming organic polymer (e.g. polyvinyl alcohol, polyethylene oxide, polyvinyl pyrollidone, polyacrylamide, hydroxyethyl cellulose and methyl cellulose). The mixture may be in powdered form which is then introduced into water for use or the material may be made in the form of a sachet or envelope made of the organic polymer, containing the other components before being introduced into water.  Other components which may be present include glycerol and polyethylene oxide as plasticizers, and kieselguhr, magnesium oxide, zinc oxide, sodium carbonate, sodium phosphate, sodium fluoride, wetting agents, pigments and flavouring agents.ALSO:A dental impression material comprises a water soluble (e.g sodium, potassium or ammonium) alginate, a gelling agent therefor (e.g. calcium or lead sulphate) and 2-25% by weight of a water soluble film forming organic polymer (e.g. polyvinyl alcohol, polyethylene oxide, polyvinyl pyrollidone, polyacrylamide, hydroxyethyl cellulose and methyl cellulose).  The mixture may be in powdered form which is then introduced into water for use or the material may be made in the form of a sachet or envelope made of the organic polymer, containing the other components before being introduced into water.  Other components which may be present include glycerol and polyethylene oxide as plasticisers, and kieselguhr, magnesium oxide, zinc oxide, sodium carbonate, sodium phosphate, sodium fluoride, wetting agents, pigments and flavouring agents.
BACKGROUND: The inflammatory factor interferon (IFN)-γ is related to the occurrence and development of systemic lupus erythematosus (SLE). The vitamin D receptor (VDR) has an anti-inflammatory effect and its downregulation is involved in the onset of SLE. Our previous studies have confirmed that the expression of VDR in SLE peripheral blood mononuclear cells (PBMCs) is downregulated, which is negatively correlated with disease activity and inflammation. However, the mechanism underlying VDR downregulation in SLE is unknown.
METHODS: Based on the results of computer simulation analysis, the expression of VDR and four microRNAs (miR-17-3p, miR-34a, miR-346, and miR-125b) in SLE PBMC cells was analyzed under proinflammatory cytokine IFN‑γ treatment, and miR-125b was identified as the target miRNA. The relationship between IFN‑γ, miR-125b, and VDR was further assessed in THP‑1 cells.
RESULTS: We showed that IFN‑γ inhibited the expression of VDR and miR-125b. Further study revealed that VDR mRNA was positively correlated with miR-125b in THP‑1 cells after IFN‑γ intervention. After transfection of miR-125b mimic or inhibitor, the expression of VDR in the miR-125b inhibitor group was lower than in the control group and miR-125b mimic group, while expression in the control group was lower than in miR-125b mimic group. Transfection of miR-125b inhibitor into THP‑1 cells could further promote the ability of IFN‑γ to inhibit VDR.
CONCLUSION: The decrease in VDR expression promotes development of inflammation and SLE. These data suggest that miR-125b may mediate inflammatory factor IFN-γ-induced downregulation of VDR in the pathogenesis of SLE.
Cellular senescence is closely associated with the pathogenesis of sepsis. However, the diagnostic and prognostic value of senescence-related genes remain unclear. In this study, 866 senescence-related genes were collected from CellAge. The training cohort, GSE65682, which included 42 control and 760 sepsis samples, was obtained from the Gene Expression Omnibus (GEO). Feature selection was performed using gene expression difference detection, LASSO analysis, random forest, and Cox regression. TGFBI and MAD1L1 were ultimately selected for inclusion in the multivariate Cox regression model. Clustering based on the expressions of TGFBI and MAD1L1 was significantly associated with sepsis characteristics and prognoses (all P < 0.05). The risk signature served as a reliable prognostic predictor across the GSE65682, GSE95233, and GSE4607 cohorts (pooled hazard ratio = 4.27; 95% confidence interval [CI] = 1.63-11.17). Furthermore, it also served as a robust classifier to distinguish sepsis samples from control cases across 14 cohorts (pooled odds ratio = 5.88; 95% CI = 3.54-9.77). Single-cell RNA sequencing analyses from five healthy controls and four sepsis subjects indicated that the risk signature could reflect the senescence statuses of monocytes and B cells; this finding was then experimentally validated in THP-1 and IM-9 cells in vitro (both P < 0.05). In all, a senescence-related gene signature was developed as a prognostic and diagnostic biomarker for sepsis, providing cut-in points to uncover underlying mechanisms and a promising clinical tool to support precision medicine.
No overdoses of MAXALT were reported during clinical trials.

Rizatriptan 40 mg (administered as either a single dose or as two doses with a 2-hour interdose interval) was generally well tolerated in over 300 patients; dizziness and somnolence were the most common drug-related adverse effects.

In a clinical pharmacology study in which 12 subjects received rizatriptan, at total cumulative doses of 80 mg (given within four hours), two subjects experienced syncope and/or bradycardia. One subject, a female aged 29 years, developed vomiting, bradycardia, and dizziness beginning three hours after receiving a total of 80 mg rizatriptan (administered over two hours); a third degree AV block, responsive to atropine, was observed an hour after the onset of the other symptoms. The second subject, a 25 year old male, experienced transient dizziness, syncope, incontinence, and a 5-second systolic pause (on ECG monitor) immediately after a painful venipuncture. The venipuncture occurred two hours after the subject had received a total of 80 mg rizatriptan (administered over four hours).

In addition, based on the pharmacology of rizatriptan, hypertension or other more serious cardiovascular symptoms could occur after overdosage. Gastrointestinal decontamination, (i.e., gastric lavage followed by activated charcoal) should be considered in patients suspected of an overdose with MAXALT. Clinical and electrocardiographic monitoring should be continued for at least 12 hours, even if clinical symptoms are not observed.

The effects of hemo- or peritoneal dialysis on serum concentrations of rizatriptan are unknown.